Marrone bio innovations inc (MBII)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Cash flows from operating activities
Net loss

-40,282

-37,175

-32,637

-20,755

-18,873

-20,213

-21,991

-26,038

-28,553

-30,925

-31,354

-30,026

-29,424

-31,071

-34,291

-36,888

-41,090

-43,728

-48,931

-53,532

-53,258

-51,659

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,785

2,349

1,890

1,810

1,867

1,890

1,931

1,993

2,001

2,044

2,079

2,119

2,162

2,235

2,590

2,953

3,271

3,510

3,368

3,207

2,926

2,581

2,211

1,701

1,280

976

0

0

0

Gain on disposal of equipment

0

-

-

-

-

-

-

-

-

-363

-365

-73

-126

-135

-131

-54

38

39

1

-123

-247

-243

0

0

0

-

-

-

-

Right of use assets amortization

812

805

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation

4,035

3,686

2,446

2,141

1,917

1,850

1,700

1,818

2,023

2,114

2,368

2,511

2,634

2,669

2,915

2,953

3,338

3,811

3,845

4,018

4,123

4,555

4,762

4,434

3,573

2,300

0

0

0

Non-cash interest expense

265

277

400

417

456

994

1,273

1,588

1,870

1,596

1,469

1,402

1,337

1,329

1,293

1,195

999

803

634

517

648

780

893

1,439

3,113

4,315

0

0

0

Loss on issuance of August 2019 warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of financial instruments

-

-

-

-

-

-

-5,273

-5,273

-5,273

-96

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in estimated fair value of financial instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Loss on extinguishment of debt, net

-

-

-

-

-

-2,196

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on extinguishment of debt, related party

-

-

-

-

-

9,183

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of investment securities premiums discounts, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10

0

0

0

-

-

-

-

Net changes in operating assets and liabilities:
Accounts receivable

1,075

2,622

3,691

2,679

4,407

-1,065

1,203

-1,072

-3,721

193

-186

1,251

3,379

1,245

666

1,592

2,524

560

-1,246

-1,049

-3,074

-1,997

1,221

362

2,469

950

0

0

0

Accounts receivable from related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-903

162

223

962

767

0

0

0

Inventories

-1,001

-599

-535

-725

-2,493

-1,603

-490

817

1,912

1,345

928

368

-425

-582

-1,365

-2,611

-3,215

-3,580

-3,394

-2,650

-1,816

-73

2,152

6,329

8,224

7,845

0

0

0

Prepaid Expenses and other assets

272

327

511

582

448

-34

923

719

140

144

-437

-524

-222

-189

-508

-415

26

-142

-209

-264

-266

309

205

-2,564

-1,634

-1,374

0

0

0

Deferred cost of product revenues

-

-

-

-

-

-

116

-349

-934

375

1,259

1,384

1,763

1,092

536

429

293

-201

-635

-1,427

-968

-1,064

0

0

0

-

-

-

-

Accounts payable

3,546

1,204

-654

753

-217

-2,028

-735

-1,449

-407

2,305

471

811

456

-588

1,163

-1,027

-1,265

-3,486

-1,587

-926

-2,708

1,667

-2,511

-184

4,281

1,682

0

0

0

Accrued and other liabilities

1,413

3,223

7,508

3,635

246

-857

-1,686

-335

978

2,599

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-219

-2,454

-1,718

-511

-76

1,013

2,961

2,838

1,895

3,017

1,041

913

1,141

0

0

0

Accrued interest due to related parties

-

-

-

-

-

-1,614

-807

-1,588

-790

4

2

-4

-6

443

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Lease Liability

685

627

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-619

-681

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

1,943

2,552

3,416

2,494

1,873

1,853

1,099

29

-300

-660

-39

-108

503

3,737

3,758

3,464

0

0

0

Net cash used in operating activities

-19,981

-21,339

-19,006

-15,124

-17,329

-19,425

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred revenue from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

168

181

278

461

492

563

720

589

671

-186

-599

-618

-866

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-22,145

-24,307

-25,845

-29,317

-34,526

-36,174

-37,533

-39,996

-37,413

-35,935

0

0

0

-

-

-

-

Cash flows from investing activities
Payment of future contingent consideration in connection with previous asset purchase

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sale of property, plant, equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

13

13

6

0

0

0

-

-

-

-

Purchases of property, plant and equipment

315

296

302

287

334

580

954

1,167

1,128

849

431

276

243

209

326

348

672

1,653

3,169

4,975

8,988

13,002

13,094

12,053

8,578

3,966

0

0

0

Net cash used in investing activities

-7,350

-6,793

-6,695

-287

-334

-580

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchase of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49

0

0

0

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,716

0

0

0

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-243

-209

-326

-348

-672

-1,646

-3,162

-4,713

-6,312

671

0

0

0

-

-

-

-

Cash flows from financing activities
Proceeds from issuance of common stock, net of offering costs

-

-

-

-

-

34,486

34,485

34,461

30,008

8,188

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of debt

-

-

-

-

-

2,000

6,000

6,000

6,000

4,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from secured borrowings

33,981

29,376

30,447

27,216

25,038

21,844

23,799

19,831

19,748

16,228

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reductions in secured borrowings

30,633

27,822

26,988

25,357

21,363

21,046

23,502

20,341

18,146

14,952

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Repayment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-261

-260

-259

-372

-403

-435

-478

-433

-408

-378

0

0

0

-

-

-

-

Financing costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of capital leases

-

-

-

-

-

-

-

-

-

420

692

827

762

821

886

1,180

1,695

1,983

1,974

2,003

1,496

1,073

812

350

273

229

0

0

0

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,139

0

0

0

Exercise of stock options

0

-

-

-

-

-

-

-

-

17

22

32

32

31

0

0

0

-

-

-

-

1,305

1,469

1,367

1,099

250

0

0

0

Proceeds from employee stock purchase plan

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exercise of warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of debt

1,839

1,715

397

251

259

254

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

23,865

16,163

13,030

1,586

16,005

36,953

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from exercise of common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

0

0

0

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

14,346

14,287

14,347

38,628

22,670

22,334

22,251

-725

44,779

46,133

0

0

0

-

-

-

-

Net (decrease) increase in cash and cash equivalents and restricted cash

-3,466

-11,969

-12,671

-13,825

-1,658

16,948

15,900

11,610

12,018

-9,780

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,229

-11,824

8,963

-12,528

-15,486

0

0

0

-

-

-

-

-

-

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Supplemental disclosure of cash flow information
Cash paid for interest

1,221

1,175

868

795

850

2,772

3,460

5,536

5,956

5,993

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,643

-

2,122

2,249

2,297

2,102

2,041

1,748

1,515

1,692

0

0

0

Supplemental disclosure of non-cash investing and financing activities
Property, plant and equipment included in accounts payable and accrued liabilities

0

-

26

-180

-139

51

-56

474

405

245

331

4

47

21

506

511

381

499

-31

-618

-1,704

204

0

0

0

-

-

-

-

Equipment acquired under capital leases

-

-

-

-

-

-

-

-

-

-

-

-

-

1,586

0

0

0

-

-

-

-

834

2,323

2,496

2,482

2,106

0

0

0

Embedded derivative liability associated with bridge loan

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of debt to equity

-

-

-

-

-

10,000

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest added to the principal of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,623

0

0

0

Conversion of bridge loan (convertible note) to equity

-

-

-

-

-

6,000

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of debt, related party to equity

-

-

-

-

-

35,000

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of accrued liabilities into equity associated with the granting of restricted stock units

-

-

-

-

-

205

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Embedded derivative liability associated with bridge loan

-

-

-

-

-

573

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-